Barasertib is effective in the discontinuation of AURKB for the treatment of pediatric acute leukemia [4], and AURKB is also detected in many solid tumors, such as gastric cancer [5, 6], glioblastoma [7], bladder cancer [8], and clear cell renal cell carcinoma [9]. This evidence concerns the gene AURKB and urinary bladder carcinoma.